Immix Biopharma (IMMX) Net Cash Flow (2021 - 2026)

Immix Biopharma (IMMX) has 6 years of Net Cash Flow data on file, last reported at -$14.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 736.67% year-over-year to -$14.7 million; the trailing twelve-month figure through Mar 2026 stood at $62.2 million (up 564.44% YoY), and the FY2025 full-year result was $76.2 million, up 43272.74% from the prior year.
• Net Cash Flow slipped to -$14.7 million in Q1 2026, from $78.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $78.0 million in Q4 2025 to a low of -$14.7 million in Q1 2026.
• A 5-year average of $3.6 million and a median of -$1.8 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow plunged 2016.24% in 2022 and jumped 4032.39% in 2025, its largest moves.
• Tracing IMMX's Net Cash Flow over 5 years: stood at -$3.5 million in 2022, then soared by 39.54% to -$2.1 million in 2023, then climbed by 5.73% to -$2.0 million in 2024, then jumped by 4032.39% to $78.0 million in 2025, then sank by 118.8% to -$14.7 million in 2026.
• Business Quant data shows IMMX's Net Cash Flow at -$14.7 million in Q1 2026, $78.0 million in Q4 2025, and $4.3 million in Q3 2025.